| Ytd | -18.58% | |
| 1y | -0.93% |
| Open | 4.34 | Prev Close | 4.19 | Low | 4.21 | High | 4.40 | Mkt Cap | 33.50M |
| Vol | 25.90K | Avg Vol | 33.99K | EPS | -3.64 | P/E | N/A | Forward P/E | N/A |
| Beta | 0.85 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 4.42 | 200-d Avg | 5.00 | 1yr Est | 0.00 |
RADX News
Wall Street analysts began coverage on top names, including a bullish rating on Radiopharm Theranost
HC Wainwright & Co. analyst Robert Burns initiates coverage on Radiopharm Theranostics (NASDA
Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a cl
Key Findings from the AACR Abstract and PosterMeaningful tumor uptake of 177Lu-RAD202 was observed a
The U.S. multicenter, open-label, single arm Phase 2b clinical trial is evaluating the diagnostic pe
Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a cl
On track to share data from first two dose levels in 2H 2026Targeting KLK3 and leveraging the dual e
Radiopharm Theranostics says Phase 2b interim data showing 90% MRI concordance for RAD 101, with fin
Radiopharm Theranostics (ASX: RAD, "Radiopharm" or the "Company"), a clinical-stage
Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage b
Program and Business Updates18F-RAD101 – Small molecule targeting fatty acid synthase radiolabeled w
Radiopharm Ventures, LLC, is a joint venture created in 2022 between MD Anderson Cancer Center and R
Benzinga examined the prospects for many investors' favorite stocks over the last week — here
B. Riley Securities analyst Yuan Zhi reiterates Radiopharm Theranostics (NASDAQ:RADX) with a Buy
Radiopharm Theranostics shares rise after interim Phase 2b data showed 92% MRI concordance for RAD 1
RADX: 471% | Radiopharm Theranostics' Interim Data From The First Twelve Patients In Its U.S. Ph
The interim analysis showed that 92% (11/12) of the patients treated with RAD 101 achieved concordan
Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage b
Previous comprehensive preclinical proof-of-concept Biodistribution studies of RAD 402 in mouse xeno
Early patient data from Phase 2b clinical trial showed significant and selective tumor uptake in bra
Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, "Radiopharm" or the "Company"), a c
Preliminary data from first three patients in Phase 2b imaging clinical trial of RAD 101 show uptake
